Seven abstracts on filgotinib accepted by EULAR 2017
May 15 2017 - 4:02PM
Mechelen, Belgium; 15 May 2017, 22.00 CET
- Galapagos NV (Euronext & NASDAQ: GLPG) announces
the acceptance of seven abstracts from several clinical and
pre-clinical studies with the investigational agent filgotinib in
rheumatoid and psoriatic arthritis, by the Annual European Congress
of Rheumatology organized by the European League Against Rheumatism
(EULAR) 2017, held in Madrid from 14-17 June. Following is a list
of accepted abstracts:
"Long term safety and efficacy of filgotinib in
a Phase 2b open label extension study in patients with rheumatoid
arthritis: results up to 144 weeks"
"The JAK1-selective inhibitor filgotinib reduces
multiple markers of inflammation linked to various pathologic cell
types and processes in rheumatoid arthritis patients"
"Monotherapy with the JAK1-selective inhibitor
filgotinib displays an anti-inflammatory biomarker profile in
rheumatoid arthritis patients"
"The JAK1-selective inhibitor filgotinib
regulates both enthesis and colon inflammation in a mouse model of
psoriatic arthritis"
"The JAK1-selective inhibitor filgotinib
inhibits inflammation pathways observed in an IL23-induced
psoriatic arthritis mouse model"
"Effects of the JAK1-selective inhibitor
filgotinib on multibiomarker disease activity scores in patients
with active rheumatoid arthritis and an inadequate response to
methotrexate"
"Effect of baseline serum CRP levels on clinical
efficacy in rheumatoid arthritis patients treated with filgotinib:
post-hoc analysis from two phase 2b studies"
All abstracts are available on the website of
the EULAR 2017 Congress.
Filgotinib is an investigational drug and its efficacy and
safety have not been established.For information about the studies
with filgotinib: www.clinicaltrials.govFor more information about
filgotinib: www.glpg.com/filgotinib
About filgotinibGalapagos and Gilead
entered into a global collaboration for the development and
commercialization of filgotinib in inflammatory indications.
Following the Phase 2 DARWIN and FITZROY results, filgotinib is
currently being investigated in the FINCH Phase 3 program in
rheumatoid arthritis, the DIVERSITY Phase 3 program in Crohn's
disease and in the SELECTION Phase 2b/3 study in ulcerative
colitis. Furthermore, filgotinib is being studied in Phase 2
studies for small bowel and fistulizing Crohn's disease, cutaneous
lupus erythematosus (CLE), Sjögren's syndrome, ankylosing
spondylitis (TORTUGA), and psoriatic arthritis (EQUATOR).
About EULARThe European League Against
Rheumatism (EULAR) is the organization which represents the
patient, health professional and scientific societies of
rheumatology of all the European nations. EULAR endeavors to
stimulate, promote, and support the research, prevention, treatment
and rehabilitation of rheumatic diseases. In line with UEMS, EULAR
defines rheumatology as including rheumatic diseases of the
connective tissue, locomotor and musculoskeletal systems.
About GalapagosGalapagos (Euronext & NASDAQ: GLPG) is
a clinical-stage biotechnology company specialized in the discovery
and development of small molecule medicines with novel modes of
action. Our pipeline comprises Phase 3, Phase 2, Phase 1,
pre-clinical, and discovery programs in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications. We
have discovered and developed filgotinib: in collaboration with
Gilead we aim to bring this JAK1-selective inhibitor for
inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 530
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& CorporateCommunications+1 781 460 1784 |
Director
Communications+31 6 53 591 999communications@glpg.com |
Paul van der
HorstDirector IR & Business Development+31 6 53 725 199 |
|
ir@glpg.com |
|
Forward-Looking StatementsThis release may contain
forward-looking statements, including statements regarding
Galapagos' strategic ambitions, the anticipated timing of clinical
studies with filgotinib and the progression and results of such
studies. Galapagos cautions the reader that forward-looking
statements are not guarantees of future performance.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent
with such forward-looking statements, they may not be predictive of
results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements
(including that data from the ongoing and planned clinical research
programs may not support registration or further development of
filgotinib due to safety, efficacy or other reasons), Galapagos'
reliance on collaborations with third parties (including its
collaboration partner for filgotinib, Gilead), and estimating the
commercial potential of Galapagos' product candidates. A further
list and description of these risks, uncertainties and other risks
can be found in Galapagos' Securities and Exchange Commission (SEC)
filings and reports, including in Galapagos' most recent annual
report on form 20-F filed with the SEC and subsequent filings and
reports filed by Galapagos with the SEC. Given these uncertainties,
the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based or
that may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements, unless
specifically required by law or regulation.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/bbccdc14-f169-4d5a-ac97-99e11f9cf268
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Oct 2023 to Oct 2024